Novo is currently in a golden age of growth. Over the last five years, its trailing-12-month revenue grew by 109%, reaching ...

Novo Nordisk’s Phase 3 REDEFINE 1 study results for CagriSema have sparked a mixed reaction, with the drug achieving a 22.7% weight loss at 68 weeks, slightly edging out Lilly’s Zepbound at 22.5%.

Taking the Guesswork Out of Novo Nordisk Bull Call Spreads When it comes to bullish multi-leg options strategies, the Bull Call Spread is incredibly popular because of its leverage and simplicity.